Cara Therapeutics to Present at May Investor Conferences

STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences in May:

BofA Securities 2022 Healthcare ConferenceTuesday, May 10, 2022, at 2 p.m. PT / 5 p.m. ET

H.C. Wainwright Global Investment ConferenceWednesday, May 25, 2022, at 2:30 p.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:Annie Spinetta6 Degrees973-768-2170[email protected]

INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara Therapeutics203-406-3700[email protected]

You May Also Be Interested In

• Silicon Motion Technology Corporation Announces Closing of Upsized Offering of $1,150,000,000 of 0.00% Convertible Senior Notes due 2031
• BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
• Volatus Aerospace Releases Q2 2026 Financial Results